Cellbyte GTM brain

Cellbyte provides AI-powered research and expert services for pharmaceutical pricing and market access teams planning drug launches.

category

Pharma pricing and market access intelligence

market profile

  • text: Drug launches require fragmented clinical, regulatory, HTA and pricing evidence across countries, creating long manual research cycles.
  • text: The company combines a shared AI research platform with expert-led services for market access decisions.

personas

  • title: Global market access director
    pains:
    • Must compare payer evidence and launch sequence across markets with different HTA rules.
    • Needs credible, traceable evidence for consequential launch decisions.
  • title: Pricing and reimbursement analyst
    pains:
    • Manually extracts comparator, pricing and benefit-rating data from long multilingual documents.
    • Needs to validate the exact source passage behind AI outputs.
  • title: Pharma launch strategy lead
    pains:
    • Price comparisons and launch order affect potential revenue across interconnected markets.
    • Teams and outside consultants take weeks to assemble the evidence base.

icp

  • text: Global pharmaceutical manufacturers with pricing and market access teams, including large pharma with multi-country launches.
  • text: Drug developers researching oncology or other indications with complex comparator and HTA evidence across major markets.

message pillars

  • text: Shorten manual evidence research.
  • text: Make findings auditable at source.
  • text: Deliver domain expertise alongside AI.

objections

  • objection: Can we trust AI on high-stakes reimbursement questions?
    response: Inspect the linked original passages and have market access experts validate outputs; the company emphasizes source traceability.
  • objection: Will it cover our market and indication?
    response: Scope a representative comparator and HTA question with the team and verify geographic and indication coverage.
  • objection: We already use consultants and databases.
    response: Compare a sourced pilot with the existing workflow; Cellbyte also offers expert-delivered research.

competitors

  • name: IQVIA
    why: Established pharma data and services provider covering payer strategy and pricing.
  • name: Simon-Kucher
    why: Consultancy competing for pharmaceutical pricing and market access strategy work.

influencers

  • name: Daniel Moreira
    url: https://www.linkedin.com/posts/daniel-moreira-713330b8_today-many-patients-still-wait-years-to-activity-7396487133617815552-gMYA
    why: Co-founder discussing pharma market access and the company's seed round.

keywords

  • pharma market access intelligence
  • drug launch sequencing
  • pharmaceutical pricing data
  • HTA evidence research
  • drug comparator analysis
  • global reference pricing
  • AI pharma market access

voice

  • evidence-led and precise
  • pragmatic about time savings
  • expert and healthcare focused

signals

  • text: A pharma team is preparing a new multi-market launch or indication expansion.
  • text: A market access group is evaluating HTA outcomes, comparator evidence or cross-country prices.

pricing

model: unknown

motion

sales_led

channels

  • LinkedIn
  • customer case studies
  • industry conferences
  • founder-led sales

confidence

high

Founders

  • name: Felix Steinbrenner
    title: Founder/CEO
    role: CEO
    bio: Co-founder & CEO of Cellbyte. We are building AI agents to accelerate the launch and commercialization of pharmaceutical drugs. Pivoted from Last Mile Logistics in 2023: previously co-founded and led Operations at Glocally (W22), where we offered a same-day parcel delivery service to e-commerce brands like H&M. Utilizing electric vehicles only, we surpassed 150K parcels with excellent reviews, and raised >$2M from top-tier Angels and VCs (YC, Trucks,...).

Back to YC companies